CSIMarket
 


Vaxart Inc   (VXRT)
Other Ticker:  
 

Cumulative Vaxart Inc 's Working Capital Ratio for Trailing Twelve Months Period

VXRT's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

VXRT Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth -23.42 % -48.17 % -12.83 % 42.12 % 66.2 %
Y / Y Current Assets Growth -54.21 % -52.57 % -48.29 % -50.82 % -41.21 %
Working Capital Ratio for Trailing Twelve Months Period 4.58 5.17 5.3 6.08 7.68
Total Ranking # 385 # 659 # 706 # 673 # 590
Seq. Current Liabilities Growth 21.8 % -18.84 % -11.48 % -12.49 % -17.57 %
Seq. Current Assets Growth -20.25 % -19.87 % -6.03 % -23.75 % -17.39 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Despite year on year decrease in Vaxart Inc 's average Current Liabilities to $14 millions, Working Capital Ratio for Trailing Twelve Months Period to 4.58 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 44 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Vaxart Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about VXRT
Working Capital Ratio VXRT in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 45
Sector # 259
S&P 500 # 599


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
15.2 6.63 2.07
(Dec 31 2021)   (Dec 31 2019)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Aim Immunotech Inc   12.55 
Anavex Life Sciences Corp   12.54 
Creative Medical Technology Holdings Inc   12.44 
Immunovant Inc   11.93 
Scholar Rock Holding Corp  11.34 
Caribou Biosciences Inc   11.00 
Tarsus Pharmaceuticals Inc   10.68 
Jasper Therapeutics Inc   10.40 
Allogene Therapeutics inc   10.33 
Monte Rosa Therapeutics Inc   10.18 
Autolus Therapeutics Plc  10.01 
Century Therapeutics inc   9.67 
Avrobio Inc   9.64 
Argenx se  9.64 
Ambrx Biopharma Inc   9.55 
Springworks Therapeutics Inc   9.53 
Solid Biosciences Inc   9.53 
Vectivbio Holding Ag  9.14 
Turnstone Biologics Corp   9.08 
Candel Therapeutics Inc   9.06 
Biontech Se  8.79 
Elevation Oncology inc   8.68 
Passage Bio inc   8.67 
Pluri Inc   8.42 
Tscan Therapeutics Inc   8.41 
Jounce Therapeutics inc   8.37 
Athira Pharma Inc   8.25 
Black Diamond Therapeutics Inc   8.23 
Inhibrx Inc   8.21 
Allovir Inc   8.20 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com